Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs

Abstract

Over the past few years, mesenchymal stem cells (MSCs) have become of increasing interest for use in the field of regenerative medicine. To date, bone marrow (BM) has been the main source of MSCs (BM-MSCs) for both experimental and clinical studies. However, the use of MSCs derived from BM can be problematic, due to the low number of MSCs found in bone marrow aspirates and the invasive procedure associated with obtaining them. We aimed to develop a method of obtaining high numbers of purified MSCs from placental tissue with minimal expansion and to characterize their phenotype and function relative to BM-MSCs. We show here that placenta-derived MSCs (PD-MSCs) can be isolated with high numbers from whole placental tissue. However, PD-MSCs isolated from whole tissue were often found to be a mixed population of both maternal and neonatal cells. The immunological properties of PD-MSCs and BM-MSCs were compared. PD-MSCs were found to express lower levels of HLA class I and higher levels of PDL-1 and CD1a, compared to BM-MSCs. HLA-DR became upregulated in PD-MSCs following treatment with IFNγ, whereas BM-MSCs expressed constitutively low levels of HLA-DR. Whilst untreated or IFNγ-treated BM-MSCs were incapable of stimulating T cells, we observed a small T cell proliferation in response to the highest concentration of PD-MSCs when treated with IFNγ. It was noted that BM-MSCs were more immunomodulatory than PD-MSCs in this study. We therefore suggest that BM-MSCs may be better candidates for use in commercial regenerative or transplantation medicine.